Cargando…
A Maternally Sequestered, Biopolymer‐Stabilized Vascular Endothelial Growth Factor (VEGF) Chimera for Treatment of Preeclampsia
BACKGROUND: Preeclampsia is a hypertensive syndrome that complicates 3% to 5% of pregnancies in the United States. Preeclampsia originates from an improperly vascularized and ischemic placenta that releases factors that drive systemic pathophysiology. One of these factors, soluble fms‐like tyrosine...
Autores principales: | Logue, Omar C., Mahdi, Fakhri, Chapman, Heather, George, Eric M., Bidwell, Gene L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779036/ https://www.ncbi.nlm.nih.gov/pubmed/29629873 http://dx.doi.org/10.1161/JAHA.117.007216 |
Ejemplares similares
-
Maternally sequestered therapeutic polypeptides – a new approach for the management of preeclampsia
por: Bidwell, Gene L., et al.
Publicado: (2014) -
Utilizing a Kidney-Targeting Peptide to Improve Renal Deposition of a Pro-Angiogenic Protein Biopolymer
por: Mahdi, Fakhri, et al.
Publicado: (2019) -
Molecular Size Modulates Pharmacokinetics, Biodistribution, and Renal Deposition of the Drug Delivery Biopolymer Elastin-like Polypeptide
por: Kuna, Marija, et al.
Publicado: (2018) -
Pro-angiogenic therapeutics for preeclampsia
por: Eddy, Adrian C., et al.
Publicado: (2018) -
MicroRNAs targeting VEGF are related to vascular dysfunction in preeclampsia
por: Witvrouwen, Isabel, et al.
Publicado: (2021)